Our goal is to identify new early mechanisms and biomarkers associated with Alzheimer’s disease (AD), and thereby improve the development of new treatments and diagnostic tools.  We have therefore, over the years, together with national and international colleagues and collaborators, investigated the impact of AD risk factors (such as stress, inflammation, metabolic changes and amyloidogenesis) on different types of brain cells. Our scientific approach is to use translational studies primarily conducted on human samples (brain, retina, CSF and cells isolated from postmortem adult and fetal brain). By the use of such studies, we have revealed several new mechanisms and biomarkers associated with AD, including alteration of glycogen metabolism, toxicity/specificity of varios amyloid peptides and secretion of various pathology-specific molecules.